The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
- Conditions
- Urothelial Carcinoma
- Interventions
- Other: Normal salineDrug: Intravesical 2000mg/52.6ml gemcitabine instillation
- Registration Number
- NCT03062059
- Lead Sponsor
- National Cancer Center, Korea
- Brief Summary
The aim of this study is to evaluate the effectiveness and safety of intravesical gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma.
- Detailed Description
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Outcome Measures:
Two year recurrence-free survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group.
Secondary Outcome Measures:
Time to recurrence in intravesical 2000mg/52.6ml gemcitabine instillation group and control group.
Overall survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group.
Safety of intravesical 2000mg/52.6ml gemcitabine instillation.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 134
- The subjects who will undergo nephroureterectomy due to ureter or renal pelvis urothelial carcinoma
- Male or female aged 18 or over 18 years and not more than 85 years who were diagnosed as upper urinary tract urothelial carcinoma
- Normal bone marrow function: Hemoglobin >10 g/dL, ANC >1,500/mm3, platelet count>100,000/mm3
- Normal bladder volume and function
- Normal liver function:
- Bilirubin ≤ 1.5 times of upper normal limit
- AST/ALT ≤ 1.8 times of upper normal limit
- Alkaline phosphatase ≤ 1.8 times of upper normal limit
- Subjects who voluntarily decided to participate and signed the written informed consent
- Concomitant bladder cancer
- Subjects who underwent any treatment due to bladder cancer within 3 years
- Prior hypersensitivity reaction history to gemcitabine
- Neurogenic bladder
- Subjects who underwent chemotherapy due to any cancer within 6 months
- Subjects who underwent neoadjuvant chemotherapy due to ureter or renal pelvis urothelial carcinoma
- Hypersensitivity to gemcitabine or component of gemcitabine
- In case of co-administration of gemcitabine and cisplatin in severe renal failure patients
- Moderate to severe liver dysfunction or renal dysfunction (Glomerular filtration rate < 30 mL/min)
- Severe bone marrow suppression
- Severe infection
- Female who are pregnant or has a possibility of pregnancy
- Nursing female
- Interstitial pneumonia or pulmonary fibrosis which is evident on chest x-ray and symptomatic
- Subjects who are undergoing radiotherapy on chest
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Normal saline Normal saline Intravesical 52.6ml normal saline instillation during radical nephroureterectomy followed by normal saline bladder irrigation Gemcitabine Intravesical 2000mg/52.6ml gemcitabine instillation Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy followed by normal saline bladder irrigation
- Primary Outcome Measures
Name Time Method Two year recurrence-free survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. The recurrence will be assessed by CT scan and cystoscopic exam. Two years Analysis of recurrence status at 2 years from intravesical instillation of 2000mg/52.6ml gemcitabine
- Secondary Outcome Measures
Name Time Method Time to recurrence in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. The recurrence will be assessed by CT scan and cystoscopic exam. six years Analysis of time from starting intravesical instillation of 2000mg/52.6ml gemcitabine to recurrence
Overall survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. six years Analysis of survival status due to any cause at six years from intravesical instillation of 2000mg/52.6ml gemcitabine
CT cystography finding at one week after surgery. one week Evaluation of leakage at CT cystography at one week from intravesical instillation of 2000mg/52.6ml gemcitabine
International Prostate Symptom Score questionnaire at one week after surgery. one week Evaluation of survey with International Prostate Symptom Score questionnaire a one week after surgery
Trial Locations
- Locations (5)
National Cancer Center
🇰🇷Goyang, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of